Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

BACKGROUND: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of action and non-overlapping toxicity profiles. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, Raymond S., Greene, John, McCaffrey, John, Parker, Imelda, Helanova, Sylva, Baird, Anne-Marie, Teiserskiene, Ausra, Lim, Marvin, Matthews, Helen, Deignan, Olwyn, Feeney, John, Thirion, Pierre G., Finn, Stephen P., Kelly, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427915/
https://www.ncbi.nlm.nih.gov/pubmed/34512801
http://dx.doi.org/10.1177/17588359211042691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427915/
https://www.ncbi.nlm.nih.gov/pubmed/34512801
http://dx.doi.org/10.1177/17588359211042691

Ejemplares similares